Heron Therapeutics, Inc.
NASDAQ:HRTXBiotechnology
+$0.01 today
- Market cap
- $50.25M
- Beta
- 1.57
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.16
Volume 3.60M
Average 2.90M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Heron Therapeutics, Inc.
NASDAQ:HRTX
Intrinsic Alpha fair value
Locked
Current Price
$0.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +12.9% | +4.0% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +12.9% over three years. Forward estimates point to Revenue at +4.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
SELLAS Life Sciences Group, Inc. NASDAQ:SLS | $1.59B | $7.86 | Not rated | -47.3 | +917.81% |
OmniAb, Inc. NASDAQ:OABI | $716.17M | $4.91 | Not rated | -5.2 | +201.20% |
Eupraxia Pharmaceuticals Inc. NASDAQ:EPRX | $548.02M | $8.15 | Not rated | -8.5 | -1.45% |
Protalix BioTherapeutics, Inc. AMEX:PLX | $257.17M | $3.05 | Overvalued | 11.0 | +75.86% |
Invivyd, Inc. NASDAQ:IVVD | $171.58M | $0.58 | Not rated | -3.9 | -81.42% |
MediWound Ltd. NASDAQ:MDWD | $166.54M | $12.90 | Not rated | -7.0 | -19.69% |
Protara Therapeutics, Inc. NASDAQ:TARA | $155.77M | $2.53 | Not rated | -2.7 | -62.73% |
Neonc Technologies Holdings, Inc. NASDAQ:NTHI | $141.66M | $4.91 | Not rated | -3.0 | -41.32% |
Coherus Oncology, Inc. NASDAQ:CHRS | $81.21M | $0.53 | Not rated | -1.3 | -64.81% |
Continue the stock analysis
Jump to another research area for this company.